Laura J van 't Veer Selected Research

Neoadjuvant Therapy

4/2024	Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
3/2024	Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
3/2024	Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
12/2023	Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
12/2023	Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
12/2022	Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
1/2022	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
7/2016	Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
7/2016	Adaptive Randomization of Neratinib in Early Breast Cancer.
5/2015	Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura J van 't Veer Research Topics

Disease

36	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2002
33	Neoplasms (Cancer) 03/2024 - 06/2002
7	Triple Negative Breast Neoplasms 03/2024 - 07/2016
5	Neoplasm Metastasis (Metastasis) 10/2023 - 01/2002
4	Residual Neoplasm 03/2024 - 05/2015
2	Pathologic Complete Response 12/2023 - 12/2022
2	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2019
2	Circulating Neoplastic Cells 01/2022 - 01/2022
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 12/2023
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2021
1	Carcinogenesis 01/2016
1	Melanoma (Melanoma, Malignant) 01/2014
1	Ataxia Telangiectasia (Louis Bar Syndrome) 03/2012
1	Hypersensitivity (Allergy) 03/2012
1	Telangiectasis (Telangiectasia) 03/2012
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2012
1	Familial Breast Cancer 04/2004

Drug/Important Bio-Agent (IBA)

15	Hormones (Hormone)IBA 03/2024 - 12/2011
11	Biomarkers (Surrogate Marker)IBA 03/2024 - 07/2016
5	Estrogen ReceptorsIBA 04/2024 - 11/2017
5	Circulating Tumor DNAIBA 03/2024 - 01/2022
5	Trastuzumab (Herceptin)FDA Link 01/2024 - 07/2016
4	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 01/2002
4	Messenger RNA (mRNA)IBA 12/2023 - 06/2002
4	InterferonsIBA 12/2023 - 01/2014
4	Tamoxifen FDA LinkGeneric 12/2022 - 11/2017
3	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2019
2	Epidermal Growth Factor (EGF)IBA 04/2024 - 01/2022
2	Cell-Free Nucleic AcidsIBA 03/2024 - 01/2023
2	pertuzumabIBA 01/2024 - 11/2021
2	Phenobarbital (Luminal)FDA Link 01/2024 - 12/2023
2	human ERBB2 proteinIBA 01/2024 - 07/2016
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2023 - 11/2021
2	Proteins (Proteins, Gene)FDA Link 12/2023 - 01/2022
2	ErbB Receptors (EGF Receptor)IBA 06/2023 - 01/2022
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2022
2	Phosphotransferases (Kinase)IBA 01/2016 - 03/2012
1	Peptides (Polypeptides)IBA 03/2024
1	trebananibIBA 12/2023
1	Progesterone Receptors (Progesterone Receptor)IBA 12/2023
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2023
1	Nucleic AcidsIBA 01/2023
1	Goserelin (Zoladex)FDA Link 12/2022
1	STA 9090IBA 12/2022
1	Retinoblastoma ProteinIBA 01/2022
1	Cyclin-Dependent Kinase 4IBA 01/2022
1	PhosphoproteinsIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	CyclinsIBA 01/2022
1	Thymidine KinaseIBA 01/2022
1	Ado-Trastuzumab EmtansineIBA 11/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021
1	Raloxifene Hydrochloride (Evista)FDA Link 08/2021
1	Docetaxel (Taxotere)FDA Link 10/2020
1	AnthracyclinesIBA 10/2020
1	Capecitabine (Xeloda)FDA Link 10/2020
1	Formaldehyde (Formol)FDA Link 11/2017
1	ParaffinIBA 11/2017
1	neratinibIBA 07/2016
1	Carboplatin (JM8)FDA LinkGeneric 07/2016
1	veliparibIBA 07/2016
1	VemurafenibIBA 01/2014
1	Cystine (L-Cystine)IBA 10/2013
1	Glutamine (L-Glutamine)FDA Link 10/2013
1	AntiportersIBA 10/2013
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 10/2013
1	Immunoglobulins (Immunoglobulin)IBA 03/2012
1	Ataxia Telangiectasia Mutated ProteinsIBA 03/2012
1	Plasminogen Activator Inhibitor 1IBA 01/2012
1	Insulin-Like Growth Factor I (IGF-1)IBA 04/2004
1	Insulin-Like PeptidesIBA 04/2004
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 04/2004

Therapy/Procedure

20	Therapeutics 01/2024 - 01/2002
10	Neoadjuvant Therapy 04/2024 - 05/2015
6	Drug Therapy (Chemotherapy) 12/2023 - 01/2002
5	Adjuvant Chemotherapy 01/2024 - 10/2006
4	Immunotherapy 04/2024 - 01/2022
3	Segmental Mastectomy (Lumpectomy) 01/2024 - 11/2017
3	Radiotherapy 01/2021 - 01/2012
2	Mastectomy (Mammectomy) 01/2019 - 11/2017
1	Investigational Therapies (Experimental Therapy) 12/2023
1	Palliative Care (Palliative Therapy) 10/2023
1	Precision Medicine 01/2023